Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Alemtuzumab, Fludarabine, Melphalan, and Thiotepa As Reduced-Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Inborn Errors of Immunity

Thomas Pfeiffer, Stephanie Hyde, Shalini Shenoy, Melissa Mavers, Robert J. Hayashi, Feng Gao, Lisa Madden, Troy Quigg, Michael J. Eckrich, Sima Bhatt, Jeffrey J. Bednarski

Blood (2024) 144 (Supplement 1): 375.

https://doi.org/10.1182/blood-2024-194650

Published: 2024

Journal Articles

Health-Related Quality-of-Life Improvements after Exagamglogene Autotemcel in Patients with Severe Sickle Cell Disease

Akshay Sharma, Haydar Frangoul, Franco Locatelli, Kevin H.M. Kuo, Monica Bhatia, Markus Y Mapara, Michael J. Eckrich, Suzan Imren, Nanxin Li, Jaime Rubin, Siyu Zhang, Tina Liu, William Hobbs, Stephan A. Grupp

Blood (2024) 144 (Supplement 1): 7453.

https://doi.org/10.1182/blood-2024-204112

Published: 2024

Journal Articles

Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease

Blood (2024) 144 (Supplement 1): 4954.

https://doi.org/10.1182/blood-2024-204001

Published: 2024

Journal Articles

An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease

Blood (2024) 143 (25): 2654–2665.

https://doi.org/10.1182/blood.2023023301

Published: 2024

Includes: Supplemental data

Journal Articles

Regimen Intensity and Age Affect Transplant-Related Outcomes after Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Registry Study

Blood (2023) 142 (Supplement 1): 4904.

https://doi.org/10.1182/blood-2023-182532

Published: 2023

Journal Articles

Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplant for Hyperinflammatory Inborn Errors of Immunity

Rebecca A. Marsh, Soyoung Kim, Kyle Hebert, Christopher C. Dvorak, MD, Victor Aquino, MD, K. Scott Scott Baker, MD MS, Deepak Chellapandian, MD, Blachy Davila, MD, Christine Duncan, MD, Michael J. Eckrich, MD MPH, George E. Georges, MD, Timothy S. Olson, MD PhD, Michael A Pulsipher, MD, Shalini Shenoy, MD, Elizabeth Stenger, MD, Mark Vander Lugt, MD, Lolie C. Yu, MD, Andrew Gennery, MD, Mary Eapen, MBBS, MS

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-139930

Published: 2020

Journal Articles

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Severe Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Adetola A. Kassim, MDMS, Josu de la Fuente, Ali Debsan Alahmari, MBBS, MD MNAMS, Michael J. Eckrich, MD MPH, Rabi Hanna, MD, Nathalie Dhedin, MD, Biljana N. Horn, MD, Vandy Black, MDMSc, Roseane V Gouveia, Adriana Seber, MDMS, Belinda Pinto Simões, MD PhD, Thalita Cristina de Mello Costa, MD, Renato Guerino-Cunha, Carmem M. S. Bonfim, MDPhD, Roberto Luiz da Silva, Nelson Hamerschlak, MD PhD, Juliana Folloni Fernandes, MD, Michael Kent, MDBS, Satya Prakash Yadav, MBBS, MD, Erfan Nur, MDPhD, Mohsen Alzahrani, Ben Carpenter, PhD, William Tse, MD, Maria Isabel, Hemalatha G Rangarajan, MD, Ibrahim Ahmed, MD, Adeseye Michael Akinsete, MBBS, Courtney D. Fitzhugh, MD, Kathryn A. Culos, PharmD, Leena Karnik, FRCPath, MRCP, James Connelly, MD, Carrie Kitko, MD, Jennifer Andrews, MDMSc, Karina L Wilkerson, NP, MSN, Robert Brodsky, Tatsuki Koyama, Michael R. DeBaun, MD MPH

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-141771

Published: 2020

Journal Articles

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)

Minoo Battiwalla, MD, Carlos Bachier, MD, Vikas Bhushan, MD, Michael J. Eckrich, MD MPH, Alireza Eghtedar, MD, Haydar Frangoul, MD, Suman Kambhampati, MD, Shahbaz Malik, MD, Peter A. McSweeney, MD, Jeremy Pantin, MBBS, Aravind Ramakrishnan, MD, Hana Safah, MD, Paul J Shaughnessy, MD, Betsy Blunk, BSN, RN, BMTCN, Tonya Cox, BSN, RN, Rocky Billups, MS, Charles F. Lemaistre, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-139121

Published: 2020

Journal Articles

Development of a Multi-Center Cohort to Evaluate Long-Term Outcomes and Late Effects Following Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Initiative

Elizabeth Stenger, MD, Allistair Abraham, MD, Curtis D Travers, MPH, Hemalatha G. Rangarajan, MD, Diane Hsu, MD, Sonali Chaudhury, MBBS,MD, Kimberly A. Kasow, DO, Michael J. Eckrich, MD MPH, Alexander I. Ngwube, MD, Julie Kanter, MD, Gregory M Guilcher, MDBSc,FRCPC, John T. Horan, MDMPH, Lakshmanan Krishnamurti, MD, Shalini Shenoy, MD

Blood (2017) 130 (Supplement 1): 3271.

https://doi.org/10.1182/blood.V130.Suppl_1.3271.3271

Published: 2017

Journal Articles

Post-Transplant Donor Lymphocyte Infusion with Methotrexate Prophylaxis Is Associated with Low Incidence of Relapse after CD34-Selected, T Cell-Depleted Haploidentical Donor Stem Cell Transplantation Regardless of NK Alloreactivity

Michael J Eckrich, MD MPH, Stacy Epstein, PharmD, Carrie Barnhart, RN, Javier Oesterheld, MD, Darci Grochowski, PA, Mark Cannon, BA, Andrew L Gilman, MD

Blood (2015) 126 (23): 3166.

https://doi.org/10.1182/blood.V126.23.3166.3166

Published: 2015

Journal Articles

The Effect of Transplant Center Characteristics On Survival After Pediatric Hematopoietic Cell Transplantation

Michael J Eckrich, MD, MPH, Jennifer Le-Rademacher, PhD, J. Douglas Rizzo, MD, MS, K. Scott Baker, MD, MS, Deepika Bhatla, MD, David K. Buchbinder, M.D., M.S.H.S., Kenneth R. Cooke, MD, Reggie Duerst, MD, Andrew Gilman, MD, Haydar Frangoul, MD, Neena Kapoor, MD, Nancy A. Kernan, MD, Michael Verneris, MD, Mary Eapen, MBBS

Blood (2012) 120 (21): 762.

https://doi.org/10.1182/blood.V120.21.762.762

Published: 2012

Journal Articles

Effect of Race on Outcomes After Allogeneic Hematopoietic Cell Transplantation for Severe Aplastic Anemia

Michael J Eckrich, MD, MPH, Kwang W Ahn, PhD, Zhiwei Wang, MS, H. Joachim Deeg, MD, Mary M. Horowitz, MD, Mary Eapen, MBBS

Blood (2011) 118 (21): 1020.

https://doi.org/10.1182/blood.V118.21.1020.1020

Published: 2011

Journal Articles

Transplant Conditioning Regimens and Outcomes After Allogeneic Hematopoietic Cell Transplantation (HCT) In Children and Adolescents with Acute Lymphoblastic Leukemia (ALL)

James Tracey, BS, Mei-Jie Zhang, PhD, Kathleen A Sobocinski, MS, Elizabeth L. Thiel, MD, Michael J. Eckrich, MD, MPH, Marcelo C Pasquini, MD, MS, Wael Saber, MD, MS, Daniel J. Weisdorf, MD, Mary M. Horowitz, MD, MS, Mary Eapen, MBBS

Blood (2010) 116 (21): 3506.

https://doi.org/10.1182/blood.V116.21.3506.3506

Published: 2010

NARROW

Alemtuzumab, Fludarabine, Melphalan, and Thiotepa As Reduced-Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Inborn Errors of Immunity

Health-Related Quality-of-Life Improvements after Exagamglogene Autotemcel in Patients with Severe Sickle Cell Disease

Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease

An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease

Regimen Intensity and Age Affect Transplant-Related Outcomes after Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Registry Study

Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplant for Hyperinflammatory Inborn Errors of Immunity

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Severe Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)

Development of a Multi-Center Cohort to Evaluate Long-Term Outcomes and Late Effects Following Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Initiative

Post-Transplant Donor Lymphocyte Infusion with Methotrexate Prophylaxis Is Associated with Low Incidence of Relapse after CD34-Selected, T Cell-Depleted Haploidentical Donor Stem Cell Transplantation Regardless of NK Alloreactivity

The Effect of Transplant Center Characteristics On Survival After Pediatric Hematopoietic Cell Transplantation

Effect of Race on Outcomes After Allogeneic Hematopoietic Cell Transplantation for Severe Aplastic Anemia

Transplant Conditioning Regimens and Outcomes After Allogeneic Hematopoietic Cell Transplantation (HCT) In Children and Adolescents with Acute Lymphoblastic Leukemia (ALL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only